FCH
LCTX icon

Freestone Capital Holdings’s Lineage Cell Therapeutics LCTX Stock Holding History

Freestone Capital Holdings’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,000
Closed -$8.8K – 778
2020
Q4 		$8.8K Hold
5,000
– – ﹤0.01% 878
2020
Q3 		$4.68K Buy
+5,000
New +$4.42K ﹤0.01% 891

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Freestone Capital Holdings's LCTX Position: Q1 2021 in Review

Freestone Capital Holdings sold out of Lineage Cell Therapeutics (LCTX) in Q1 2021, closing a stake of 5,000 shares — an estimated $8.8K sold.

Freestone Capital Holdings first reported a position in LCTX in Q3 2020 and held it in 2 quarters. The position peaked at $8.8K in Q4 2020. 102 funds tracked by Wall St. Rank hold LCTX as of Q1 2021.

  • Freestone Capital Holdings reported no remaining Lineage Cell Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Freestone Capital Holdings sold 5,000 Lineage Cell Therapeutics shares in Q1 2021, an estimated $8.8K.
  • Freestone Capital Holdings first reported a position in Lineage Cell Therapeutics in Q3 2020 and held it in 2 quarters.
  • Freestone Capital Holdings's Lineage Cell Therapeutics position peaked at $8.8K in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2021.

Based on Freestone Capital Holdings's 13F filing for Q1 2021, filed 17 May 2021.